Menu
Not yet recruiting NCT06709157

Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients

Observational Tuberculosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: P24 antigens and antibody, zeihl - Nelsen stain, culture on Lowenstein jensen media, Molecular detection of antibiotic resistance.
Who it may be relevant to
Registry conditions: Tuberculosis. Basic parameters: 16 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is one of the top 10 causes of mortality worldwide. It is estimated that in 2017, 10 million people were infected with TB, and 1.6 million died from the disease, including 0.3 million people with human immunodeficiency virus (HIV) infection . TB remains the primary killer of HIV-positive individuals. TB incidence is falling at about 2% per year . Airborne transmission of M. tuberculosis typically causes TB infection in both immunocompetent and immunocompromised hosts and the disease is symptomatic and contagious .

Detailed description

TB and HIV infections are strictly linked together. TB is the most common opportunistic infection and causes high morbidity rate among people living with HIV. Because of the decrease in cell-mediated immunity, HIV alters the pathogenesis of TB, thereby expressively increasing the risk of TB in HIV-positive patients and eventually leading to more severe complications and forms of TB.

Interventions

  • Diagnostic test P24 antigens and antibody
    estimation of antigens and antibodies to diagnose HIV
  • Diagnostic test zeihl - Nelsen stain
    staining sputum from patients with HIV to detect tubercle bacilli
  • Diagnostic test culture on Lowenstein jensen media
    spenciem will be inoculated on LJ media and kept for 2-8 weeks, to see small white colonies
  • Diagnostic test Molecular detection of antibiotic resistance
    to see the pattern of antibiotic resistance of tubercle bacilli

Primary outcome measures

  • The Prevalance of tubercuolsis in immunocompetent patients suffereing from chronic chest problems [Time frame: December 2024- June 2025]
  • The prevalence of tuberculosis in HIV patients [Time frame: December 2024- June 2025]

Eligibility criteria

Inclusion criteria

  • Patients with chronic chest disease

Exclusion criteria

  • Patients with other respiratory or infectious diseases.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-control

Study locations

Egypt · 1 center
  • Faculty of medicine — Sohag

Identifiers

NCT: NCT06709157 · Soh-Med-24-08--05PD

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗